The FDA extended until April 26 the public comment period for AquaBounty Technologies' biotech salmon, which grows twice as fast as traditional fish, after receiving nearly 30,000 responses so far. The agency will evaluate the comments and consider how to proceed, FDA spokeswoman Morgan Liscinsky said. Preliminary assessments said no major environmental impact was posed by the fish.

Full Story:

Related Summaries